Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer
NCT02426281Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Jun 2015
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel in pancreatic ductal adenocarcinoma (PDAC), sponsored by Samsung Medical Center. Started Jun 2015; status: completed.
02
Drugs
paclitaxel
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02426281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02426281.